549 Stereotactic Radiosurgery for Non-Functioning Pituitary Adenoma Recurrence With Low Dose 12 Gy
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: The existing literature presents varying opinions on the appropriate dosage of stereotactic radiosurgery (SRS) for the recurrence of nonfunctional pituitary adenomas (NPAr). While it is theorized that administering higher doses may reduce the likelihood of recurrence, there is a growing concern that such doses could compromise neurological function by damaging nearby structures. METHODS: An institutional review board-approved retrospective study was conducted for patients who underwent SRS for NPAr from 2006 to 2022. Collected information included demographics, treatment parameters, preoperative and postoperative neurologic and endocrinologic function, and postoperative hormone management. Patients treated with 12 Gy were compared to all other patients with a dosage range of 1/13 to 28/50.4. RESULTS: A total of 63 patients were included in the study, 23 of which were treated with 12 Gy and 40 treated with different doses of radiation. The average follow up was 21 and 34 months, respectively. No significant differences were found in gender, age, tumor volume, preoperative hormone replacement, endocrine function, diabetes insipidus, and cranial nerve (CN) deficit between groups (p = 0.117, p = 0.531, p = 0.482, p = 0.793, p = 0.439, p = 0.494, and p = 0.535, respectively). Additionally, no significant differences were found in postoperative hormone replacement, hormone replacement in 1 year, diabetes insipidus, CN deficit, CN deficit in 1 year, and recurrence post radiation (p = 0.603, p = 0.399, p = 0.652, p = 0.535, p = 0.214, and p = 0.701, respectively). CONCLUSIONS: SRS treatment of NPAr using a low dose of 12 Gy is as effective as higher radiation doses while minimizing the risk of functional neurological deficits and showed noninferiority to compared modalities.
Fields of Study & Subjects
Pituitary Gland Disorders and Treatments
Meningioma and schwannoma management
Neuroendocrine Tumor Research Advances
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 164–165
- Publication date
- 26 March 2026
- Language
- EN